849106-01-0

Basic information

• Product Name: 1-BOC-4-(4-CHLOROPHENYL)-4-PIPERIDINEDICARBOXYLIC ACID METHYL ESTER
• Synonyms: 1-BOC-4-(4-CHLOROPHENYL)-4-PIPERIDINEDICARBOXYLIC ACID METHYL ESTER;1-Boc-4-p-Chlorophenyl-4-methoxycarbonylpiperidine
• CAS NO: 849106-01-0
• Molecular Formula: C₁₈H₂₄ClNO₄
• Molecular Weight: 353.844
• Mol File: 849106-01-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BOC-4-(4-CHLOROPHENYL)-4-PIPERIDINEDICARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(4-CHLOROPHENYL)-4-PIPERIDINEDICARBOXYLIC ACID METHYL ESTER(849106-01-0)
• EPA Substance Registry System: 1-BOC-4-(4-CHLOROPHENYL)-4-PIPERIDINEDICARBOXYLIC ACID METHYL ESTER(849106-01-0)

Safety Data

• Hazardous Substances Data: 849106-01-0(Hazardous Substances Data)

Usage

Type

Chemical compound

Usage

Organic synthesis and drug development

Structure

Methyl ester derivative of BOC-protected piperidine carboxylic acid with a 4-chlorophenyl group attached to the piperidine ring

Potential Applications

a. Pharmaceutical industry as a building block for the synthesis of various bioactive molecules
b. Precursor for the preparation of drug candidates
c. Controlled release and targeted delivery of active ingredients in drug formulations due to BOC protecting group
d. Development of new materials
e. Research tool in biochemistry and medicinal chemistry

Functional Groups

a. BOC protecting group
b. Methyl ester
c. 4-chlorophenyl group
d. Piperidine ring
e. Carboxylic acid

Properties

a. Stability due to BOC protecting group
b. Reactivity with various reagents for further functionalization
c. Solubility in organic solvents
d. Potential bioactivity due to the presence of the piperidine ring and 4-chlorophenyl group

Synthesis

Likely involves the reaction of a BOC-protected piperidine carboxylic acid with a 4-chlorophenyl group-containing compound, followed by methyl esterification

Purification

May require techniques such as column chromatography or recrystallization to obtain the desired purity

Safety

As with any chemical compound, proper handling, storage, and disposal protocols should be followed to minimize risks to human health and the environment.

Upstream product

• 644981-94-2 4-(4-chloro-phenyl)-piperidine-1,4-dicarboxylic acid mono-tert-butyl ester 
• 74-88-4 methyl iodide 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 118753-70-1 N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine 
• 218451-34-4 4-(4-chloro-phenyl)-4-cyano-piperidine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 885500-46-9 tert-butyl 4-(4-chlorophenyl)-4-formylpiperidine-1-carboxylate 
• 849106-02-1 4-(4-chloro-phenyl)-piperidine-4-carboxylic acid methyl ester 
• 672927-26-3 4-(4-chloro-phenyl)-4-hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester 
• 934347-94-1 4-(4-chloro-phenyl)-piperidine-4-carboxylic acid methyl ester hydrochloride 

Relevant articles and documents

ACYL SULFONAMIDE NAV1.7 INHIBITORS

The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (I)

CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

Piperidine derivatives and methods of use

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment

Chemokine receptor antagonists and methods of use thereof

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.